Moderna Reports Second Quarter 2023 Financial Results and Provides Business Updates
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/9/2026
- S&P 500 falls as AI worries hit software makers
- Brent crude hits six-week high near $97 as Houthi strike targets Saudi Aramco
- Qualcomm stock surges 9.5% on Amazon AI deal & 25M share warrant
- Energy stocks rise premarket as oil prices climb on Middle East supply fears
- Novartis shares plunge 10% as failed drug trial clouds growth outlook
- Harry and Meghan surprised by King Charles' letter on their status
- Citi initiates UiPath coverage with Buy rating and $23 target
- S&P 500 falls as AI worries hit software makers
- WestPark Capital Starts Akebia Therapeutics (AKBA) at Buy
- After an 18% summer selloff in chip stocks, Citi asks what comes next
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Moderna (MRNA) Tops Q2 EPS by 32c
August 3, 2023 6:34 AM EDT(Updated - August 3, 2023 7:00 AM EDT)
Moderna (NASDAQ: MRNA) reported Q2 EPS of ($3.62), $0.32 better than the analyst estimate of ($3.94). Revenue for the quarter came in at $344 million versus the consensus estimate of $307.65 million.
Company expecting 2023 COVID-19 vaccine sales of $6 billion to $8... More
Moderna (MRNA) Guides FY23 Covid-19 Vax Revenue of $6B-$8B
August 3, 2023 6:33 AM EDTModerna (MRNA) Guides FY23 Covid-19 Vax Revenue of $6B-$8B
... More